HBM Holdings Partner Doses First Patient in SKB378 COPD Study

MT Newswires Live

Jun 10

HBM Holdings (HKG:2142) said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.

The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.

The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.

In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.

The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2642410373"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642410373\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642410373?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 13:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642410373","market":"nz","top_or_hot":-1,"title":"HBM Holdings Partner Doses First Patient in SKB378 COPD Study","media":"MT Newswires Live","content":"<html><body><p> HBM Holdings (HKG:2142) said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.</p><p>The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.</p><p>The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.</p><p>In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.</p><p>The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings Partner Doses First Patient in SKB378 COPD Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings Partner Doses First Patient in SKB378 COPD Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-10 13:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> HBM Holdings (HKG:2142) said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.</p><p>The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.</p><p>The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.</p><p>In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.</p><p>The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642410373","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642410373","pubTimestamp":1781070453,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HBM Holdings  said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","02142":"和铂医药-B","BK1161":"生物科技","BK4588":"碎股","DRAM":"Roundhill Memory ETF","BK1574":"生物医药B类股"},"translate_title":"HBM Holdings合作伙伴为SKB378 COPD研究中的首例患者进行给药","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/eb223e33d40a2eb3e7ccb9dd56904804","symbols_score_info":{"DRAM":1.5,"02142":1},"content_text":"HBM Holdings (HKG:2142) said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}